Abstract
Antibody engineering has developed very intensively since the invention of the hybridoma technology in 1975, and it now can generate therapeutic agents with high specificity and reduced adverse effects. Indeed, antibodies have become one of the most innovative therapeutic agents in recent years, with some landing in the top 10 bestselling pharmaceutical drugs. New antibodies are being approved every year, in different formats and for treating various illnesses, including cancer, autoimmune inflammatory diseases, metabolic diseases and infectious diseases. In this review, I summarize current progress in innovative engineered antibodies. Overall, this progress has led to the approval by regulatory authorities of more than 100 antibody-based molecules, with many others at various stages of clinical development, indicating the high growth potential of the field.
【저자키워드】 antibody engineering, human antibodies, therapeutic antibodies, Antibody formats, Mechanisms of action, 【초록키워드】 Inflammatory diseases, antibodies, Diseases, antibody, Cancer, drugs, adverse effects, specificity, metabolic disease, therapeutic agent, Autoimmune, growth, Stage, approval, clinical development, illnesses, regulatory authority, generate, approved, reduced, New, 【제목키워드】 antibody, current,